BACKGROUND: Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene result in defective Cl- transport and cause chronic bacterial infections in the upper and lower airways of cystic fibrosis (CF) patients. Ivacaftor is a CFTR potentiator that improves Cl- transport in CF patients with at least 1 copy of the G551D mutation. Resveratrol is also a potent CFTR potentiator that increases determinants of mucociliary transport. The objective of this study is to determine whether resveratrol and ivacaftor improve Cl- secretion in G551D CFTR over either agent alone. METHODS: Fisher rat thyroid cells (FRT) transfected with G551D CFTR and human sinonasal epithelial cells (HSNE) containing the CFTR G551D mutation were subjected to pharmacologic manipulation of transepithelial ion transport in Ussing chambers. Activity was further evaluated using whole-cell patch clamp methods in G551D FRT cells. RESULTS: In G551D FRT cells, resveratrol (100 μM) and ivacaftor (10 μM) significantly increased Cl- transport (change in short-circuit current, δISC = μA/cm2 ) compared with single-agent and dimethylsulfoxide vehicle controls (resveratrol + ivacaftor 4.97 ± 0.57 vs ivacaftor 0.74 ± 0.12 vs resveratrol 2.96 ± 0.52 vs control 0.74 ± 0.12; p < 0.001). Maximal Cl- secretion (20 μM forskolin) was also significantly enhanced (p < 0.0001). Activity was confirmed in G551D HSNE (resveratrol + ivacaftor 4.48 ± 0.39 vs ivacaftor 1.05 ± 0.11 vs. resveratrol 0.84 ± 0.3 vs control, 0.0 ± 0.02; p < 0.001), and whole-cell patch clamp analysis in G551D FRT cells (resveratrol + ivacaftor -2535 ± 179.3 pA vs ivacaftor -1408.9 ± 101.3 pA vs resveratrol; -766.2 ± 71.2 pA; p < 0.0001). CONCLUSION: Additive improvement in G551D CFTR-mediated Cl- secretion suggests that resveratrol could enhance ivacaftor therapy in these patients and improve CF-related rhinosinusitis.
BACKGROUND: Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene result in defective Cl- transport and cause chronic bacterial infections in the upper and lower airways of cystic fibrosis (CF) patients. Ivacaftor is a CFTR potentiator that improves Cl- transport in CFpatients with at least 1 copy of the G551D mutation. Resveratrol is also a potent CFTR potentiator that increases determinants of mucociliary transport. The objective of this study is to determine whether resveratrol and ivacaftor improve Cl- secretion in G551DCFTR over either agent alone. METHODS: Fisher rat thyroid cells (FRT) transfected with G551DCFTR and human sinonasal epithelial cells (HSNE) containing the CFTRG551D mutation were subjected to pharmacologic manipulation of transepithelial ion transport in Ussing chambers. Activity was further evaluated using whole-cell patch clamp methods in G551D FRT cells. RESULTS: In G551D FRT cells, resveratrol (100 μM) and ivacaftor (10 μM) significantly increased Cl- transport (change in short-circuit current, δISC = μA/cm2 ) compared with single-agent and dimethylsulfoxide vehicle controls (resveratrol + ivacaftor 4.97 ± 0.57 vs ivacaftor 0.74 ± 0.12 vs resveratrol 2.96 ± 0.52 vs control 0.74 ± 0.12; p < 0.001). Maximal Cl- secretion (20 μM forskolin) was also significantly enhanced (p < 0.0001). Activity was confirmed in G551D HSNE (resveratrol + ivacaftor 4.48 ± 0.39 vs ivacaftor 1.05 ± 0.11 vs. resveratrol 0.84 ± 0.3 vs control, 0.0 ± 0.02; p < 0.001), and whole-cell patch clamp analysis in G551D FRT cells (resveratrol + ivacaftor -2535 ± 179.3 pA vs ivacaftor -1408.9 ± 101.3 pA vs resveratrol; -766.2 ± 71.2 pA; p < 0.0001). CONCLUSION: Additive improvement in G551DCFTR-mediated Cl- secretion suggests that resveratrol could enhance ivacaftor therapy in these patients and improve CF-related rhinosinusitis.
Authors: Frank W Virgin; Steven M Rowe; Mary B Wade; Amit Gaggar; Kevin J Leon; K Randall Young; Bradford A Woodworth Journal: Am J Rhinol Allergy Date: 2012 Jan-Feb Impact factor: 2.467
Authors: Frank W Virgin; Christopher Azbell; Daniel Schuster; Jumin Sunde; Shaoyan Zhang; Eric J Sorscher; Bradford A Woodworth Journal: Laryngoscope Date: 2010-07 Impact factor: 3.325
Authors: Nichole Dean; Neel K Ranganath; Brandon Jones; Shaoyan Zhang; Daniel Skinner; Steven M Rowe; Eric J Sorscher; Bradford A Woodworth Journal: Int Forum Allergy Rhinol Date: 2014-04-14 Impact factor: 3.858
Authors: Dong-Jin Lim; Justin McCormick; Daniel Skinner; Shaoyan Zhang; Jeffrey B Elder; John G McLemore; Mark Allen; John Martin West; Jessica W Grayson; Steven M Rowe; Bradford A Woodworth; Do-Yeon Cho Journal: Int Forum Allergy Rhinol Date: 2019-12-23 Impact factor: 3.858
Authors: Do-Yeon Cho; Shaoyan Zhang; Daniel F Skinner; Dong Jin Lim; Catherine Banks; Jessica W Grayson; Guillermo J Tearney; Steven M Rowe; Bradford A Woodworth Journal: Int Forum Allergy Rhinol Date: 2021-10-26 Impact factor: 5.426
Authors: Guido Veit; Dillon F Da Fonte; Radu G Avramescu; Aiswarya Premchandar; Miklos Bagdany; Haijin Xu; Dennis Bensinger; Daniel Stubba; Boris Schmidt; Elias Matouk; Gergely L Lukacs Journal: J Cyst Fibros Date: 2019-10-31 Impact factor: 5.482
Authors: Victor Emanuel Miranda Soares; Thiago Inácio Teixeira do Carmo; Fernanda Dos Anjos; Jonatha Wruck; Sarah Franco Vieira de Oliveira Maciel; Margarete Dulce Bagatini; Débora Tavares de Resende E Silva Journal: Mol Cell Biochem Date: 2021-09-16 Impact factor: 3.396
Authors: Daniel M Beswick; Stephen M Humphries; Connor D Balkissoon; Matthew Strand; Eszter K Vladar; David A Lynch; Jennifer L Taylor-Cousar Journal: Ann Am Thorac Soc Date: 2022-01